Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

16 Jan 2020

Abstract excerpt

There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL patients who received either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31945157
DOI: 10.1182/bloodadvances.2019000875

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPMID 31945157Read ↗

MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.Semantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read ↗

Your chemo is no good here: management of high-risk MCL.Semantic proximity Read ↗

Double-Hit Large B Cell Lymphoma.Semantic proximity Read ↗

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndromeSemantic proximity Read ↗

MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.Semantic proximity Read ↗

Emerging Strategies in Treating Double Hit Lymphomas.Semantic proximity Read ↗

Biology of double-hit B-cell lymphomasSemantic proximity Read ↗

MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approachesSemantic proximity Read ↗

Aggressive B-cell lymphoma: chasing the target.Semantic proximity Read ↗

Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.